ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
63 572,18
0,25%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Aeglea BioTherapeutics Inc (AGLE)

  7. Aeglea BioTherapeutics Inc (AGLE) Actualités

AGLE Aeglea BioTherapeutics Inc

12,01
0,00 (0,00%)
26 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Aeglea BioTherapeutics Inc AGLE NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 12,01 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
12,01 12,01
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
25/4/202422:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/4/202422:40EDGAR2Form SC 13D/A - General statement of acquisition of..
25/4/202422:21EDGAR2Form 8-K - Current report
02/4/202422:36EDGAR2Form ARS - Annual Report to Security Holders
01/4/202422:06EDGAR2Form DEF 14A - Other definitive proxy statements
20/3/202412:14EDGAR2Form PRE 14A - Other preliminary proxy statements
18/3/202421:06EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
18/3/202413:31EDGAR2Form 8-K - Current report
14/3/202421:12EDGAR2Form POS AM - Post-Effective amendments for registration..
28/11/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202313:33EDGAR2Form 8-K - Current report
27/11/202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202322:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202322:32EDGAR2Form 3 - Initial statement of beneficial ownership of..
27/11/202322:27EDGAR2Form 3 - Initial statement of beneficial ownership of..
27/11/202322:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202314:30PRNUSAeglea BioTherapeutics Announces Name Change to Spyre..
23/11/202302:45EDGAR2Form 8-K - Current report
22/11/202323:00PRNUSAeglea BioTherapeutics Announces Grants of Inducement Awards
15/11/202323:18EDGAR2Form S-1/A - General form for registration of securities..
15/11/202323:14EDGAR2Form 8-K - Current report
14/11/202321:13EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/11/202322:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:06EDGAR2Form 8-K - Current report
09/11/202322:05PRNUSAeglea BioTherapeutics Reports Third Quarter 2023 Financial..
03/11/202322:00PRNUSAeglea BioTherapeutics Announces Grants of Inducement Awards
31/10/202301:00PRNUSAeglea BioTherapeutics to Participate in Upcoming November..
27/10/202303:53EDGAR2Form DEF 14A - Other definitive proxy statements
24/10/202315:00EDGAR2Form 8-K - Current report
07/10/202303:40EDGAR2Form PRER14A - Preliminary Proxy Soliciting materials
05/10/202323:13EDGAR2Form 8-K - Current report
03/10/202300:02PRNUSAeglea BioTherapeutics Announces Grants of Inducement Awards
25/9/202322:02EDGAR2Form 8-K - Current report
14/9/202323:03PRNUSAeglea BioTherapeutics to Participate in Upcoming September..
08/9/202323:05EDGAR2Form 8-K - Current report
07/9/202314:40PRNUSAeglea BioTherapeutics Announces Reverse Stock Split
05/9/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202322:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/9/202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202322:06EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/9/202313:06EDGAR2Form 8-K - Current report
05/9/202313:00PRNUSAeglea BioTherapeutics Expands Executive Leadership Team..
11/8/202313:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202313:02EDGAR2Form 8-K - Current report
11/8/202313:01EDGAR2Form 8-K - Current report
11/8/202313:00PRNUSAeglea BioTherapeutics Reports Second Quarter 2023 Financial..
08/8/202303:51EDGAR2Form PRE 14A - Other preliminary proxy statements
07/8/202322:25EDGAR2Form S-3 - Registration statement under Securities Act of..
28/7/202315:01EDGAR2Form SC 13G - Statement of acquisition of beneficial..
27/7/202313:01EDGAR2Form 8-K - Current report

Dernières Valeurs Consultées

NASDAQ
AGLE
Aeglea BioTherapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés